Released: October 19, 2020
Defense Health Program
Department of Defense Breast Cancer Research Program
Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)
The Fiscal Year 2021 (FY21) Defense Appropriations Bill has not been signed into law. Although FY21 funds have not been appropriated for the Department of Defense Breast Cancer Research Program (BCRP), the BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities. This pre-announcement should not be construed as an obligation by the Government.
The FY21 Defense Appropriations Act is anticipated to provide funding to the Department of Defense BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).
Subject to the FY21 Congressional appropriation for BCRP funding, FY21 BCRP Program Announcements and General Application Instructions for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the Program Announcements are released.
Applications submitted to the FY21 BCRP must address one or more of the following overarching challenges:
- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
- Eliminate the mortality associated with metastatic breast cancer
|Award Mechanism||Eligibility||Key Mechanism Elements||Funding|
|Breakthrough Award||Investigators at all academic levels (or equivalent)||
The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
Funding Levels 1 and 2
Funding Levels 3 and 4
Funding Level 1
Funding Level 1 – Partnering PI Option
Funding Level 2
Funding Level 2 – Partnering PI Option
Funding Level 2 – Population Science and Prevention Studies
Funding Level 2 – Population Science and Prevention Studies – Partnering PI Option
Funding Level 3
Funding Level 3 – Partnering PI Option
Funding Level 4 and Funding Level 4 – Partnering PI Option
|Era of Hope Scholar Award||Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline||
|Innovator Award||Associate Professor or above (or equivalent)||
|Transformative Breast Cancer Consortium Award||Independent investigators at all academic levels (or equivalent)||
Preference will be given to applications that include one or more of the following:
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).
Point of Contact:
CDMRP Public Affairs
Last updated Tuesday, January 4, 2022